Ceftazidime Injection 1 Gm

Product Name: Ceftazidime Injection IP
Brand Name: Stef
Strength:1 GM
Packing: Single Vial Per Box

Ceftazidime Injection IP Overview:

• Drug Class: Antibiotic (Third-generation Cephalosporin)
• Purpose: Treats bacterial infections by interfering with cell wall synthesis in susceptible bacteria.
• Formulation: Available as a sterile powder for reconstitution into solution for injection.
• Administration: Administered intravenously or intramuscularly.
• Indications:
  • Used for treating severe bacterial infections such as pneumonia, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections.
  • Effective against both Gram-positive and Gram-negative bacteria.
• Dosage:
  • Dosage varies based on the type and severity of infection, as well as patient's weight and renal function.
  • Typically administered every 8 to 12 hours.
• Precautions:
  • Use caution in patients with known hypersensitivity to cephalosporins or penicillins.
  • Monitor renal function, especially in patients with pre-existing renal impairment.
  • Use with caution in patients with a history of gastrointestinal diseases, particularly colitis.
• Contraindications:
  • Hypersensitivity to cephalosporins or any component of the formulation.
  • History of severe allergic reactions to penicillins or other beta-lactam antibiotics.
• Adverse Effects:
  • Common adverse effects include diarrhea, nausea, vomiting, rash, and injection site reactions.
  • Serious adverse effects may include Clostridium difficile-associated diarrhea, allergic reactions (including anaphylaxis), and superinfections.
• Special Populations:
  • Use with caution in elderly patients and those with compromised renal function.
  • Pregnancy category B – generally considered safe for use during pregnancy.
• Storage:
  • Store dry powder at controlled room temperature.
  • Reconstituted solution should be used immediately or stored under refrigeration and used within 24 hours.
• Drug Interactions:
  • Concurrent use with nephrotoxic drugs may increase the risk of renal toxicity.
  • May reduce the efficacy of oral contraceptives, necessitating alternative contraceptive methods during treatment.
• Monitoring:
  • Monitor for signs of allergic reactions, superinfections, and renal function.
  • Periodic assessments of blood counts, renal function, and liver function may be necessary during prolonged therapy.
• Patient Counseling:
  • Complete the full course as prescribed, even if symptoms improve.
  • Report any signs of adverse effects promptly to healthcare provider.
  • Inform healthcare provider of all medications being taken concurrently.